B-lymphocyte antigen CD19–Tyrosine-protein kinase Lyn complex (CD19–LYN complex)

The CD19–LYN complex is a critical signaling node in B-lymphocytes, where the transmembrane protein CD19 acts as a scaffold for the Src-family tyrosine kinase LYN. Upon B-cell receptor (BCR) activation, LYN phosphorylates specific tyrosine residues (notably Y513 and Y482) on the cytoplasmic tail of CD19, which in turn recruits and activates downstream signaling molecules such as PI3K and Vav. This interaction creates a potent signal amplification loop that lowers the threshold for B-cell activation and promotes cell survival and proliferation. In B-cell malignancies, such as acute lymphoblastic leukemia (ALL) and various lymphomas, this complex is often constitutively active or overexpressed, driving oncogenic signaling and resistance to apoptosis. Consequently, the CD19–LYN interface and its components are major therapeutic targets, with strategies ranging from kinase inhibitors like dasatinib to CD19-directed immunotherapies and experimental immunoconjugates like B43-genistein designed to disrupt this specific signaling axis.

Other names

CD19/Lyn signaling complexCD19-Lyn interactionCD19-Lyn receptor-enzyme complexCD19-Lyn interface

Inhibition of Lyn kinase activity within the CD19 complex, disruption of the CD19-Lyn signaling amplification loop, or targeted delivery of cytotoxic agents to CD19-expressing cells.